CASI Pharmaceuticals, Inc. of BEIJING, F4, a company, filed a Form D exempt-offering notice with the SEC on 2026-01-28. The offering totals $5.0M, of which $5.0M was reported sold. Industry: Pharmaceuticals.
Showing 25 of 36 people.
| Name | Role | Location |
|---|---|---|
| Wei-Wu He | Director | Rockville, MD |
| Wei-Wu He | Executive Officer | Rockville, MD |
| Wei-Wu He | Related Person | Rockville, MD |
| James Huang | Related Person | South San Francisco, CA |
| Chunhua Y Wang | Executive Officer | Beijing, F4 |
| Wei Y Gao | Executive Officer | Beijing, F4 |
| Alexander Y Wu | Director | Rockville, MD |
| Zhenbo Su | Director | Beijing, F4 |
| Zhenbo Su | Related Person | Beijing, F4 |
| Hai Y Huang | Executive Officer | Beijing, F4 |
| Kun Y Qian | Executive Officer | Beijing, F4 |
| Thomas Folinsbee | Director | Beijing, F4 |
| Thomas Folinsbee | Related Person | Beijing, F4 |
| Xuebo Y Zeng | Director | Beijing, F4 |
| Alexander A Zukiwski | Executive Officer | Rockville, MD |
| Wei (Larry) Y Zhang | Executive Officer | Beijing, F4 |
| Wei Gao | Related Person | Beijing, F4 |
| Wei Y. Gao | Executive Officer | Beijing, F4 |
| Alexander A. Zukiwski | Executive Officer | South San Francisco, CA |
| Hai Y. Huang | Executive Officer | Beijing, F4 |
| Wei (Larry) Y. Zhang | Executive Officer | South San Francisco, CA |
| Barbara A. Krebs-Pohl | Director | South San Francisco, CA |
| Chunhua Y. Wang | Executive Officer | Beijing, F4 |
| Kun Y. Qian | Executive Officer | Beijing, F4 |
| Xuebo Y. Zeng | Director | Beijing, F4 |
| Filed | Form | Offering | Sold |
|---|---|---|---|
| 2026-04-28 | D | $5.0M | $5.0M |
| 2026-02-26 | D | $5.0M | $5.0M |
| 2026-01-28 | D | $5.0M | $5.0M |
| 2024-07-15 | D | $15.0M | $15.0M |